Global Human Microbiome-based Drugs Market

1
Global Human Microbiome-based Drugs Market
2
Summary

• The global market for human microbiome-based
  drugs and diagnostics should reach a market size
  of nearly 9.9 billion by 2024.
• Study Goals and Objectives
• The objective of this study is to review the
  development of human microbiome-based drugs and
  diagnostics and assess their market potential for
  the U.S., Europe, Japan, China and rest of world
  geographies. We are particularly interested in
  characterizing the market for microbiome-based
  drugs for various diseases that are linked with
  the dysregulation in human microbiome.
• A focus of this report is to describe the
  microbial associations of various diseases,
  present a comprehensive profile of the
  microbiome-based drugs in the clinical
  development and finally provide the projections
  on the market size of microbiome-based drugs in
  various disease areas for the time period of 2018
  to 2024.

3
(No Transcript)
4
Reasons for Doing This Study

• The human body is a home to over 100 trillion
  microbes and over 2 million microbial genes.
  Microbiome is a term that represents all of the
  microbial genes. So, the human microbiome is, in
  a sense, our second genome. Microbes residing
  inside and on the human bodies play a significant
  role in the bodys physiological functionssome
  beneficial and others harmful. Our knowledge and
  understanding of the role that microbes play in
  various diseases has grown exponentially since
  the completion of Human Microbiome Project in
  2012. This field has seen a tremendous explosion
  in research and development activities in
  microbiome-based drugs and diagnostics. The field
  has also attracted substantial public and private
  sector investments. Collectively, these
  developments have created a new sectorhuman
  microbiome-based drugs and diagnostics.

5
Intended Audience

• We have compiled a study of microbiome-based
  drugs and diagnostics that will be important in
  key end-user segments. We analyze the
  microbiome-based drug market by indication (e.g.,
  cancer, gastrointestinal diseases, metabolic
  disorders etc.), by type of product (e.g., live
  bacteria, engineered bacteria, bacterial mixtures
  etc.), and by region (i.e., the U.S. and the rest
  of the world, which includes Europe, China, Japan
  and other countries).
• We examine the microbiomes scientific basis in
  various diseases, profile the microbiome products
  under development, and review intellectual
  property, corporate alliances and investments. We
  provide a holistic review of market potential and
  product sales forecasts by disease segment, by
  product and by region for the time period of 2017
  to 2024.

6
Scope of Report

• The scope of the study includes the major
  microbiome-based drugs and diagnostics that are
  likely to be commercialized within the next eight
  years. Each product within each market is
  analyzed to determine its market status, market
  potential during the time period of 2018 to 2024.
  Microbiome intellectual property, investments and
  collaborations are discussed.
• Influencing factors, industry structure,
  challenges facing the industry and patent status
  are discussed. Research examines companies in the
  industry, corporate alliances and assay
  consumption by indication. We profile 25
  companies participating in this rapidly
  developing and evolving sector.

7
Information Sources

• Both primary and secondary information sources
  were used in preparing this study. Research
  interviewed life science companies and research
  institutions to obtain data for this study.
  Included were diagnostics, drug firms and leading
  research institutions. In addition, we compiled
  data from secondary sources, including industry,
  trade and government organizations.

8
Methodology

• Research presents an analysis of each of the key
  market segments that will be commercially
  important during the 20172024 period
  microbiome-based drugs for gastrointestinal
  disorders (ulcerative colitis, Crohns disease,
  Clostridium difficle infection, lactose
  intolerance, celiac disease, hepatic
  encephalopathy and non-alcoholic
  steatohepatitis), cancer, bacterial infections
  (recurrent bacterial vaginosis and urinary tract
  infection, dental caries), orphan diseases (urea
  cycle disorders, phenylketonuria) and metabolic
  diseases (type 2 diabetes, obesity). We also
  conducted an analysis of microbiome-based
  diagnostics in various areas of disease.

9
Full Reports
Global Human Microbiome-based Drugs Market
Contact us atBharat Book Bureau Tel 91 22
27810772 / 27810773 Email poonam_at_bharatbook.com O
ur Blog https//www.bharatbook.com/blog/ Twitter
https//twitter.com/researchbook Facebook
https//www.facebook.com/BharatBook3B LinkedIn
http//www.linkedin.com/company/bharat-book-bureau
10
THANK YOU